Maxim Group lowered shares of TrovaGene, Inc. (NASDAQ:TROV) from a buy rating to a hold rating in a research report sent to investors on Friday morning, MarketBeat.com reports.

Separately, Cantor Fitzgerald reiterated an overweight rating on shares of TrovaGene in a research report on Tuesday, August 8th.

Shares of TrovaGene (TROV) opened at $0.68 on Friday. TrovaGene has a 52-week low of $0.61 and a 52-week high of $3.50.

TrovaGene (NASDAQ:TROV) last announced its earnings results on Thursday, November 9th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.02. TrovaGene had a negative net margin of 7,960.05% and a negative return on equity of 259.94%. The business had revenue of $0.12 million for the quarter.

COPYRIGHT VIOLATION WARNING: “TrovaGene, Inc. (TROV) Rating Lowered to Hold at Maxim Group” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/14/trovagene-inc-trov-rating-lowered-to-hold-at-maxim-group.html.

Hedge funds and other institutional investors have recently made changes to their positions in the company. LMR Partners LLP acquired a new stake in shares of TrovaGene in the second quarter valued at about $151,000. Susquehanna International Group LLP boosted its position in TrovaGene by 2,781.0% during the second quarter. Susquehanna International Group LLP now owns 138,031 shares of the medical research company’s stock worth $174,000 after acquiring an additional 133,240 shares during the last quarter. KCG Holdings Inc. boosted its position in TrovaGene by 560.1% during the first quarter. KCG Holdings Inc. now owns 210,301 shares of the medical research company’s stock worth $242,000 after acquiring an additional 178,440 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in TrovaGene by 1,079.5% during the second quarter. Goldman Sachs Group Inc. now owns 278,186 shares of the medical research company’s stock worth $351,000 after acquiring an additional 254,601 shares during the last quarter. Institutional investors and hedge funds own 9.05% of the company’s stock.

About TrovaGene

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Receive News & Stock Ratings for TrovaGene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene Inc. and related stocks with our FREE daily email newsletter.